AZD7789

AZD7789 is a bispecific antibody developed by AstraZeneca. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM-3). The sponsor states: An anti-PD-1 and anti-TIM-3 bispecific antibody that simultaneously engages both immune checkpoints to enhance anti-tumour immunity. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-TIM-3 bispecific antibody. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT04931654, plans to enrol 136 participants (actual) with primary completion expected 2024-12-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.